arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2019-25-2-122-133arthyper-1811Research ArticleСтатьиArticlesАртериальная гипертензия и болезнь Альцгеймера. Пролог к нейродегенерацииArterial hypertension and Alzheimer’s disease. Prologue to neurodegenerationЛобзинВ. Ю.LobzinV. Yu.

доктор медицинских наук, профессор кафедры нервных болезней

ул. Академика Лебедева, д. 6, лит. Ж, Санкт-Петербург, Россия, 194044

 

MD, PhD, DSc, Professor, Department of Neurology Diseases

6, lit. G Akademician Lebedev str., St Petersburg, 194044 Russia

vladimirlobzin@mail.ruКолмаковаК. А.KolmakovaK. A.

невролог клиники нервных болезней

ул. Академика Лебедева, д. 6, лит. Ж, Санкт-Петербург, Россия, 194044

 

MD, Neurologist, Neurology Clinics

6, lit. G Akademician Lebedev str., St Petersburg, 194044 Russia

kris_kolmakova@mail.ruЕмелинА. Ю.EmelinA. Yu.

доктор медицинских наук, профессор, заместитель начальника кафедры нервных болезней

ул. Академика Лебедева, д. 6, лит. Ж, Санкт-Петербург, Россия, 194044

 

MD, PhD, DSc, Professor, Deputy Head, Department of Neurology Diseases

6, lit. G Akademician Lebedev str., St Petersburg, 194044 Russia

emelinand@rambler.ruhttps://orcid.org/0000-0002-6484-286XЯнишевскийС. Н.YanishevskiyS. N.

доктор медицинских наук, доцент кафедры нервных болезней

SPIN  7379-4564

ул. Академика Лебедева, д. 6, лит. Ж, Санкт-Петербург, Россия, 194044

 

MD, PhD, DSc, Professor, Department of Neurology Diseases

6, lit. G Akademician Lebedev str., St Petersburg, 194044 Russia

St Petersburg, Russia

stasya71@yandex.ruФГБВОУ ВО «ВМА им. С. М. Кирова» Минобороны РоссииРоссияKirov Military Medical AcademyRussian FederationФГБВОУ ВО «ВМА им. С. М. Кирова» Минобороны России, ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава РоссииРоссияKirov Military Medical Academy, Almazov National Medical Research CentreRussian Federation201920052019252122133Copyright © Лобзин В.Ю., Колмакова К.А., Емелин А.Ю., Янишевский С.Н., 20192019Лобзин В.Ю., Колмакова К.А., Емелин А.Ю., Янишевский С.Н.Lobzin V.Y., Kolmakova K.A., Emelin A.Y., Yanishevskiy S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1811

Нарушения когнитивных функций – глобальная медицинская и социальная проблема всего современного общества. Болезнь Альцгеймера является самым распространенным заболеванием, приводящим к развитию когнитивных нарушений и деменции. Одним из самых значимых факторов риска развития как сосудистой деменции, так и болезни Альцгеймера является артериальная гипертензия. Недавние исследования продемонстрировали роль глимфатической системы в элиминации из головного мозга β-амилоида через периваскулярные пространства Вирхова-Робена. Интерес состоит в том, что адекватное функционирование глимфатической системы в основном зависит от уровня артериального давления в течение суток и качества сна. В данной статье мы рассматриваем основные механизмы влияния артериальной гипертензии на работу глимфатической системы, повреждения вещества головного мозга и развития когнитивных нарушений.

Cognitive impairment is a global medical and social problem. Alzheimer’s disease (AD) is the most common disease leading to the development of cognitive impairment and dementia. Arterial hypertension (HTN) is considered to be the strongest risk factor for the development of both vascular dementia and AD. Recent studies have demonstrated the importance of the glymphatic system in removing β-amyloid from the brain through the perivascular Virchow–Robin spaces. The interest is that the adequate functioning of the glymphatic system mainly depends on the level of blood pressure during the day and the quality of sleep. In this article, we will consider the main mechanisms of the HTN influence on the glymphatic system, brain substance-related damage and the development of cognitive impairment.

болезнь Альцгеймераартериальная гипертензияβ-амилоидпериваскулярные пространства Вирхова-Робенаглимфатическая системациркадный профиль артериального давлениярасстройства снакогнитивные нарушенияAlzheimer’s diseasehypertensionβ-amyloidVirchow–Robin perivascular spacesglymphatic systemcircadian blood pressure profilesleep disorderscognitive impairmentReferencesKivipelto M., Helkala E.L., Laakso M.P. et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447–1451.Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. Br Med J. 2001;322(7300):1447–1451.Luchsinger J.A., Gustafson D.R. Adiposity, type 2 dia- betes, and Alzheimer’s disease. J Alzheimer’s Dis 2009; 16: 693–704.Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes and Alzheimer’s disease. J Alzheimer’s Dis. 2009;16(4):693–704.Ahtiluoto S., Polvikoski T., Peltonen M. et al. Diabetes, Alzheimer disease, and vascular dementia: a population- based neuropathologic study. Neurology 2010; 75: 1195– 1202.Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010;75(13):1195–1202.Faraco G., Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension 2013; 62: 810– 817.Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension. 2013;62(5):810–817.Kaffashian S., Dugravot A., Nabi H. et al. (2011) Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. Eur. Heart J., 32(18): 2326–2332.Kaffashian S, Dugravot A, Nabi H, Batty GD, Brunner E, Kivimäki M et al. Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. Eur Heart J. 2011;32(18):2326–2332.Diener H.C. (2011) Prevention of dementia should start 20 years before symptoms become apparent. Eur. Heart J., 32(18): 2228–2230.Diener HC. Prevention of dementia should start 20 years before symptoms become apparent. Eur Heart J. 2011;32(18):2228–2230.Zlokovic B.V. Neurovascular pathways to neurodegener- ation in Alzheimer’s disease and other disorders. Nat Rev Neurosci 2011; 12: 723–738.Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723–738.Qiu L., Ng G., Tan E.K., Liao P., Kandiah N., Zeng L. Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer’s disease mice. Sci Rep 2016; 6: 23964.Qiu L, Ng G, Tan EK, Liao P, Kandiah N, Zeng L. Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer’s disease mice. Sci Rep. 2016;6:23964.Bennett S.A., Pappas B.A., Stevens W.D., Davidson C.M., Fortin T., Chen J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 2000; 21: 207–214.Bennett SA, Pappas BA, Stevens WD, Davidson CM, Fortin T, Chen J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging. 2000;21(2):207–214.Weller R.O., Boche D., Nicoll J.A. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neu- ropathol 2009; 118: 87–102Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol. 2009;118(1): 87–102.Hughes T.M., Craft S., Lopez O.L. Review of the potential role of arterial stiffness in the pathogenesis of Alzheimer’s disease. Neurodegener Dis Manag 2015; 5: 121–135.Hughes TM, Craft S, Lopez OL. Review of the potential role of arterial stiffness in the pathogenesis of Alzheimer’s disease. Neurodegener Dis Manag 2015;5:121–135.Elkins J. S., Yaffe K., Cauley J. A., Fink H. A. et al. Pre-existing hypertension and the impact of stroke on cognitive function // Ann. Neurol. 2005. Vol. 58. N 1. P. 68–74.Elkins JS, Yaffe K, Cauley JA, Fink HA, Hillier TA, Johnston SC. Pre-existing hypertension and the impact of stroke on cognitive function. Ann Neurol. 2005;58(1):68–74.Варакин Ю.Я. Профилактика нарушений мозгового кровообращения. Очерки ангионеврологии. Ред. З.А. Суслина. М., 2005.Varakin YuYa. Stroke prevention. Essays of anioneurology, Ed. by ZA Suslin. M.: Atmosphera, 2005. 368 p. In Russian.de Leeuw F.E., van Gijn J. Vascular dementia. Pract Neurol, 2003, 3: 86–91.de Leeuw FE, van Gijn J. Vascular dementia. Pract Neurol. 2003;3:86–91.Gorelick P.B. Blood pressure and the prevention of cognitive impairment. JAMA Neurol. 2014;71:1211–3.Gorelick PB. Blood pressure and the prevention of cognitive impairment. J Am Med Assoc Neurol. 2014;71(10):1211–1213.Qiu C., Winblad B., Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487–499.Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487–499.Bellew K.M., Pigeon J.G., Stang P.E., Fleischman W., Gardner R.M., Baker W.W. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2004; 18: 208–213.Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2004;18(4):208–213.Starr J. M., Whalley L. J., Inch S., Shering P. A. Blood pressure and cognitive function in healthy old people // J. Am. Geriatr. Soc. 1993. Vol. 41. N 7. P. 153–156.Starr JM, Whalley LJ, Inch S, Shering PA. Blood pressure and cognitive function in healthy old people. J Am Geriatr Soc. 1993;41(7):153–156.Moonga I., Niccolini F., Wilson H., Pagano G., Politis M. (2017). Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer’s disease. European Journal of Neurology, 24(9), 1173–1182. doi:10.1111/ene.13374Moonga I, Niccolini F, Wilson H, Pagano G, Politis M, Alzheimer’s Disease Neuroimaging Initiative. Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer’s disease. Eur J Neurol. 2017;24 (9):1173–1182. doi:10.1111/ene.13374Верещагин Н.В., Моргунов В.А., Гулевская Т.С. Патология головного мозга при атеросклерозе и артериальной гипертонии. М., 1997;288 с.Verechshagin NV, Morgunov VA, Gulevskaya TS. Brain pathology of atherosclerosis and hypertension. M., 1997; 288 p. In Russian.Laman J.D., Weller R.O. (2013) Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J. Neuroimmune Pharmacol 8:840–856.Laman JD, Weller RO. Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J Neuroimmune Pharmacol. 2013;8(4):840–856.Gurol M.E., Viswanathan A., Gidicsin C. et al (2013) Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol 73:529–536.Gurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez-Ramirez S, Dumas A et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol. 2013;73(4):529–536.Gurol M.E., Irizarry M.C., Smith E.E. et al (2006) Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66:23–29.Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66 (1):23–29.Iliff J.J., Nedergaard M. Is there a cerebral lymphatic system? Stroke. 2013 Jun;44(6):93-95.Iliff JJ, Nedergaard M. Is there a cerebral lymphatic system? Stroke. 2013;44(6):93–95.Xie L., Kang H., Xu Q., et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. doi:10.1126/science.1241224.Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373–377. doi:10.1126/science.1241224Roher A.E., Kuo Y.M., Esh C., Knebel C., Weiss N., Kalback W., Luehrs D.C., Childress J.L., Beach T.G., Weller R.O., Kokjohn T.A. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer’s disease. Mol Med. 2003;9:112–122.Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W et al. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer’s disease. Mol Med. 2003; 9(3–4):112–122.Chabriat H., Joutel A., Dichgans M., Tournier-Lasserve E., Bousser M.G. CADASIL. Lancet Neurol. 2009; 8: 643–653.Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8(7):643–653.Zhu Y.C., Tzourio C., Soumare A. et al. Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI Markers of small vessel disease: a population-based study. Stroke. 2010;41:2483–2490.Zhu YC, Tzourio C, Soumare A, Mazoyer B, Dufouil C, Chabriat H. Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI Markers of small vessel disease: a population-based study. Stroke. 2010;41(11):2483–2490.Chen H.F., Chang-Quan H., You C., Wang Z.-R., Hui W., Liu Q.X., Si-Qing, H. (2012). The circadian rhythm of arterial blood pressure in Alzheimer disease (AD) patients without hypertension. Blood Pressure, 22(2), 101–105.Chen HF, Chang-Quan H, You C, Wang ZR, Hui W, Liu QX et al. The circadian rhythm of arterial blood pressure in Alzheimer disease (AD) patients without hypertension. Blood Press. 2012;22(2): 101–105.Salles G. F., Reboldi G., Fagard R. H., Cardoso C. R., Pierdomenico S. D., Verdecchia P., Roush G. C. (2016). Prognostic effect of the nocturnal blood pres- sure fall in hypertensive patients: The Ambulatory Blood Pressure Collaboration in Patients with Hypertension (ABC-H) meta-analysis. Hypertension, 67, 693-700.Salles GF, Reboldi G, Fagard RH, Cardoso CR, Pierdomenico SD, Verdecchia P et al. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: The Ambulatory Blood Pressure Collaboration in Patients with Hypertension (ABC-H) Meta-Analysis. Hypertension. 2016;67(4):693–700.Verdecchia P. (2000). Prognostic value of ambulatory blood pressure : Current evidence and clinical implications. Hypertension, 35, 844-851. doi:10.1161/01.HYP.35.3.844Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension. 2000;35(3):844–851. doi:10.1161/01.HYP.35.3.844Fagard R. H., Celis H., Thijs L., Staessen J. A., Clement D. L., De Buyzere M. L., De Bacquer D. A. (2008). Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension, 51, 55-61. doi:10.1161/ HYPERTENSIONAHA.107.100727Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61. doi:10.1161/HYPERTENSIONAHA.107.100727O’Rourke M. F., Safar M. E. (2005). Relationship between aortic stiffening and microvascular disease in brain and kidney: Cause and logic of therapy. Hypertension, 46, 200-204.O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension. 2005;46(1):200–204.Nagai M., Hoshide S., Ishikawa J., Shimada K., Kario K. (2008). Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. Journal of Hypertension, 26, 1636-1641.Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens. 2008;26(8):1636–1641.Bellelli G., Frisoni G. B., Lucchi E., Guerini F., Geroldi C., Magnifico F., Trabucchi M. (2004). Blunted reduction in night-time blood pressure is associated with cognitive deterioration in subjects with long-standing hypertension. Blood Pressure Monitoring, 9, 71-76.Bellelli G, Frisoni GB, Lucchi E, Guerini F, Geroldi C, Magnifico F et al. Blunted reduction in night-time blood pressure is associated with cognitive deterioration in subjects with longstanding hypertension. Blood Press Monit. 2004;9(2):71–76.van Boxtel M. P., Henskens L. H., Kroon A. A., Hofman P. A., Gronenschild E. H., Jolles J., de Leeuw P. W. (2006). Ambulatory blood pressure, asymptomatic cerebrovascular damage and cognitive function in essential hypertension. Journal of Human Hypertension, 20(1), 5-13.van Boxtel MP, Henskens LH, Kroon AA, Hofman PA, Gronenschild EH, Jolles J et sl. Ambulatory blood pressure, asymptomatic cerebrovascular damage and cognitive function in essential hypertension. J Hum Hypertens. 2006;20(1):5–13.Guo H., Tabara Y., Igase M., Yamamoto M., Ochi N., Kido T., . Kohara K. (2010). Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: The J-SHIPP study. Hypertension Research, 33(1), 32-36.Guo H, Tabara Y, Igase M, Yamamoto M, Ochi N, Kido T et al. Abnormal nocturnal blood pressure profile is associated with mild cognitive impairment in the elderly: the J‑SHIPP study. Hypertens Res. 2010;33(1):32–36.Mestre H., Tithof J., Du T., Song W., Peng W., Sweeney A. M., Kelley D. H. (2018). Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nature Communications, 9(1). doi:10.1038/s41467-018-07318-3Mestre H, Tithof J, Du T, Song W, Peng W, Sweeney AM et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat Commun. 2018;9(1):4878. doi:10.1038/s41467-018-07318-3Mancia G., Fagard R., Narkiewicz K. et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31: 1925–38.Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31 (10):1925–1938.Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of rterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013 Jul;31(7):1281-357.Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31 (7):1281–1357.Roth T. Insomnia: definition, prevalence,etiology, and consequences // J Clin Sleep Med., 2007; 3(Suppl 5): S7–10.Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(Suppl 5): S7–S10.Полуэктов М.Г., Левин Я.И. Инсомния /Сомнология и медицина сна. Избранные лекции / под ред. Я. И. Левина и М. Г. Полуэктова. – М.: Медфорум-альфа, 2013. – С. 192–220.Poluektov MG, Levin YaI. Insomnia, somnology and sleep medicine. Selected lectures. Ed. By YaI Levin and MG Poluektov. M.: Medforum-alfa, 2013. P. 192–220. In Russian.Ковальзон В.М. Основы сомнологии. Физиология и нейрохимия цикла бодрствование – сон. – М.: БИНОМ. Лаборатория знаний, 2012. – 240 с.Kovalzon VM. Physiology and neurochemistry of the cycle wakefulness — sleep. M.: BINOM, Knowledge laboratory, 2012. 240 p. In Russian.Somers V. K., Dyken M. E., Mark A. L., Abboud F. M. (1993). Sympathetic-Nerve Activity during Sleep in Normal Subjects. New England Journal of Medicine, 328(5), 303–307. doi:10.1056/nejm199302043280502Somers VK, Dyken ME, Mark AL, Abboud FM. Sympatheticnerve activity during sleep in normal subjects. New Eng J Med. 1993;328(5):303–307. doi:10.1056/nejm199302043280502Hanak V., Somers V. K. (2011). Cardiovascular and cerebrovascular physiology in sleep. Sleep Disorders, 315–325. doi:10.1016/b978-0-444-52006-7.00019-8Hanak V, Somers VK. Cardiovascular and cerebrovascular physiology in sleep. Sleep Disorders. 2011:98;315–325. doi:10.1016/b978-0-444-52006-7.00019-8ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013;31:1925–1938.Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer’s disease — friend or foe? Trends in Neurosciences. 2009:32 (12):619–628. doi:10.1016/j.tins.2009.07.006Kehoe P. G., Miners S. Love, S. (2009). Angiotensins in Alzheimer’s disease – friend or foe? Trends in Neurosciences, 32(12), 619–628. doi:10.1016/j.tins.2009.07.006Kehoe P. G., Miners S. Love, S. (2009). Angiotensins in Alzheimer’s disease – friend or foe? Trends in Neurosciences, 32(12), 619–628. doi:10.1016/j.tins.2009.07.006

The authors declare that there are no conflicts of interest present.